OCS
Oculis Holding AG
Biotechnology
Market Cap$1.89B
5Y Perf.+236.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
OCS vs DBVT vs ALKS vs RCKT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1690.08T
5Y Perf.-66.3%
ALKS
Alkermes plc
Biotechnology
Market Cap$5.83B
5Y Perf.+54.3%
RCKT
Rocket Pharmaceuticals, Inc.
Biotechnology
Market Cap$396M
5Y Perf.-91.5%
OCS vs DBVT vs ALKS vs RCKT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OCS | DBVT | ALKS | RCKT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $1.89B | $1690.08T | $5.83B | $396M |
| Revenue (TTM) | $504K | $0.00 | $1.56B | $0.00 |
| Net Income (TTM) | $-104M | $-168M | $153M | $-209M |
| Gross Margin | -28.6% | — | 65.4% | — |
| Operating Margin | -155.4% | — | 12.3% | — |
| Forward P/E | — | — | 24.5x | — |
| Total Debt | $1M | $22M | $70M | $25M |
| Cash & Equiv. | $28M | $194M | $1.12B | $78M |
OCS vs DBVT vs ALKS vs RCKT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OCS
DBVT
ALKS
RCKT
| Stock | May 21 | May 26 | Return |
|---|---|---|---|
| Oculis Holding AG (OCS) | 100 | 336.5 | +236.5% |
| DBV Technologies S.… (DBVT) | 100 | 33.7 | -66.3% |
| Alkermes plc (ALKS) | 100 | 154.3 | +54.3% |
| Rocket Pharmaceutic… (RCKT) | 100 | 8.5 | -91.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OCS vs DBVT vs ALKS vs RCKT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALKS leads in 2 of 6 categories, making it the strongest pick for profitability and margin quality and operational efficiency and capital deployment. Oculis Holding AG is the stronger pick specifically for capital preservation and lower volatility. DBVT and RCKT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
OCS
Oculis Holding AG
The Long-Run Compounder
OCS is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 236.5% 10Y total return vs ALKS's -12.0%
- Lower volatility, beta 0.79, Low D/E 1.6%, current ratio 2.37x
- Beta 0.79 vs DBVT's 1.26, lower leverage
Best for: long-term compounding and sleep-well-at-night
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.26
- +100.5% vs RCKT's -48.4%
Best for: income & stability
ALKS
Alkermes plc
The Growth Play
ALKS carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
- 9.8% margin vs OCS's -206.5%
- 5.4% ROA vs DBVT's -89.0%
Best for: growth exposure
RCKT
Rocket Pharmaceuticals, Inc.
The Defensive Pick
RCKT is the clearest fit if your priority is defensive.
- Beta 1.21, current ratio 6.38x
- 19.7% revenue growth vs DBVT's -100.0%
Best for: defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RCKT | 19.7% revenue growth vs DBVT's -100.0% |
| Quality / Margins | ALKS | 9.8% margin vs OCS's -206.5% |
| Stability / Safety | OCS | Beta 0.79 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | DBVT | +100.5% vs RCKT's -48.4% |
| Efficiency (ROA) | ALKS | 5.4% ROA vs DBVT's -89.0% |
OCS vs DBVT vs ALKS vs RCKT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
Segment breakdown not available.
OCS vs DBVT vs ALKS vs RCKT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOCSLAGGINGRCKT
Who Leads Where
ALKS leads in 2 of 6 categories
OCS leads 2 • DBVT leads 0 • RCKT leads 0 • 1 tied
Explore the data ↓RCKTRocket Pharmaceutical…
0leads
DBVTDBV Technologies S.A.
0leads
ALKSAlkermes plc
2leads
OCSOculis Holding AG
2leads
6 Total Categories
CATEGORYLEADERvs ALKSvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALKS4/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALKS7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
OCS5/6
Risk & VolatilityBeta, volatility, and downside exposure
OCS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and RCKT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to OCS's -206.5%.
| Metric | OCSOculis Holding AG | DBVTDBV Technologies … | ALKSAlkermes plc | RCKTRocket Pharmaceut… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $504,000 | $0 | $1.6B | $0 |
| EBITDAEarnings before interest/tax | -$78M | -$112M | $212M | -$208M |
| Net IncomeAfter-tax profit | -$104M | -$168M | $153M | -$209M |
| Free Cash FlowCash after capex | -$61M | -$151M | $392M | -$180M |
| Gross MarginGross profit ÷ Revenue | -28.6% | — | +65.4% | — |
| Operating MarginEBIT ÷ Revenue | -155.4% | — | +12.3% | — |
| Net MarginNet income ÷ Revenue | -206.5% | — | +9.8% | — |
| FCF MarginFCF ÷ Revenue | -121.8% | — | +25.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +28.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +33.3% | +91.5% | -4.1% | +25.0% |
ALKS leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Evenly matched — OCS and DBVT and ALKS each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | OCSOculis Holding AG | DBVTDBV Technologies … | ALKSAlkermes plc | RCKTRocket Pharmaceut… |
|---|---|---|---|---|
| Market CapShares × price | $1.9B | $1690.08T | $5.8B | $396M |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $1690.08T | $4.8B | $343M |
| Trailing P/EPrice ÷ TTM EPS | -12.01x | -0.75x | 24.47x | -1.81x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 17.01x | — |
| Price / SalesMarket cap ÷ Revenue | 2144.98x | — | 3.95x | — |
| Price / BookPrice ÷ Book value/share | 14.02x | 0.65x | 3.25x | 1.46x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.14x | — |
Evenly matched — OCS and DBVT and ALKS each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ALKS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. OCS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs RCKT's 1/9, reflecting strong financial health.
| Metric | OCSOculis Holding AG | DBVTDBV Technologies … | ALKSAlkermes plc | RCKTRocket Pharmaceut… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -81.7% | -130.2% | +8.8% | -70.8% |
| ROA (TTM)Return on assets | -61.8% | -89.0% | +5.4% | -59.6% |
| ROICReturn on invested capital | -106.8% | — | +18.9% | -62.4% |
| ROCEReturn on capital employed | -85.4% | -145.7% | +14.2% | -58.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 7 | 1 |
| Debt / EquityFinancial leverage | 0.02x | 0.13x | 0.04x | 0.09x |
| Net DebtTotal debt minus cash | -$27M | -$172M | -$1.0B | -$53M |
| Cash & Equiv.Liquid assets | $28M | $194M | $1.1B | $78M |
| Total DebtShort + long-term debt | $1M | $22M | $70M | $25M |
| Interest CoverageEBIT ÷ Interest expense | -117.78x | -189.82x | 32.30x | -41.65x |
ALKS leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
OCS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OCS five years ago would be worth $33,650 today (with dividends reinvested), compared to $837 for RCKT. Over the past 12 months, DBVT leads with a +100.5% total return vs RCKT's -48.4%. The 3-year compound annual growth rate (CAGR) favors OCS at 46.3% vs RCKT's -44.6% — a key indicator of consistent wealth creation.
| Metric | OCSOculis Holding AG | DBVTDBV Technologies … | ALKSAlkermes plc | RCKTRocket Pharmaceut… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +63.2% | +3.6% | +23.8% | +4.9% |
| 1-Year ReturnPast 12 months | +74.5% | +100.5% | +15.2% | -48.4% |
| 3-Year ReturnCumulative with dividends | +213.2% | +18.1% | +13.2% | -83.0% |
| 5-Year ReturnCumulative with dividends | +236.5% | -68.3% | +61.7% | -91.6% |
| 10-Year ReturnCumulative with dividends | +236.5% | -87.1% | -12.0% | -91.4% |
| CAGR (3Y)Annualised 3-year return | +46.3% | +5.7% | +4.2% | -44.6% |
OCS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
OCS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
OCS is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OCS currently trades 99.6% from its 52-week high vs RCKT's 49.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OCSOculis Holding AG | DBVTDBV Technologies … | ALKSAlkermes plc | RCKTRocket Pharmaceut… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 1.26x | 1.00x | 1.21x |
| 52-Week HighHighest price in past year | $32.76 | $26.18 | $36.60 | $7.39 |
| 52-Week LowLowest price in past year | $16.00 | $7.53 | $25.17 | $2.19 |
| % of 52W HighCurrent price vs 52-week peak | +99.6% | +75.3% | +95.6% | +49.1% |
| RSI (14)Momentum oscillator 0–100 | 69.7 | 47.4 | 60.5 | 48.4 |
| Avg Volume (50D)Average daily shares traded | 364K | 252K | 2.2M | 3.5M |
OCS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: OCS as "Buy", DBVT as "Buy", ALKS as "Buy", RCKT as "Buy". Consensus price targets imply 134.8% upside for DBVT (target: $46) vs 31.5% for ALKS (target: $46).
| Metric | OCSOculis Holding AG | DBVTDBV Technologies … | ALKSAlkermes plc | RCKTRocket Pharmaceut… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $50.00 | $46.33 | $46.00 | $5.00 |
| # AnalystsCovering analysts | 7 | 15 | 28 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). OCS leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallOculis Holding AG (OCS)Leads 2 of 6 categories
Loading custom metrics...
OCS vs DBVT vs ALKS vs RCKT: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is OCS or DBVT or ALKS or RCKT a better buy right now?
Alkermes plc (ALKS) offers the better valuation at 24.
5x trailing P/E, making it the more compelling value choice. Analysts rate Oculis Holding AG (OCS) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OCS or DBVT or ALKS or RCKT?
Over the past 5 years, Oculis Holding AG (OCS) delivered a total return of +236.
5%, compared to -91. 6% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: OCS returned +236. 5% versus RCKT's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OCS or DBVT or ALKS or RCKT?
By beta (market sensitivity over 5 years), Oculis Holding AG (OCS) is the lower-risk stock at 0.
79β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 59% more volatile than OCS relative to the S&P 500. On balance sheet safety, Oculis Holding AG (OCS) carries a lower debt/equity ratio of 2% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — OCS or DBVT or ALKS or RCKT?
On earnings-per-share growth, the picture is similar: Oculis Holding AG grew EPS 28.
6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OCS or DBVT or ALKS or RCKT?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -125. 0% for Oculis Holding AG — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -106. 7% for OCS. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — OCS or DBVT or ALKS or RCKT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OCS or DBVT or ALKS or RCKT better for a retirement portfolio?
For long-horizon retirement investors, Oculis Holding AG (OCS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
79), +236. 5% 10Y return). Both have compounded well over 10 years (OCS: +236. 5%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OCS and DBVT and ALKS and RCKT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.